Literature DB >> 26679929

Isolation and proliferation of umbilical cord tissue derived mesenchymal stem cells for clinical applications.

Phuc Van Pham1, Nhat Chau Truong2, Phuong Thi-Bich Le3, Tung Dang-Xuan Tran3, Ngoc Bich Vu2, Khanh Hong-Thien Bui4, Ngoc Kim Phan2.   

Abstract

Umbilical cord (UC) is a rich source of rapidly proliferating mesenchymal stem cells (MSCs) that are easily cultured on a large-scale. Clinical applications of UC-MSCs include graft-versus-host disease, and diabetes mellitus types 1 and 2. UC-MSCs should be isolated and proliferated according to good manufacturing practice (GMP) with animal component-free medium, quality assurance, and quality control for their use in clinical applications. This study developed a GMP standard protocol for UC-MSC isolation and culture. UC blood and UC were collected from the same donors. Blood vasculature was removed from UC. UC blood was used as a source of activated platelet rich plasma (aPRP). Small fragments (1-2 mm(2)) of UC membrane and Wharton's jelly were cut and cultured in DMEM/F12 medium containing 1 % antibiotic-antimycotic, aPRP (2.5, 5, 7.5 and 10 %) at 37 °C in 5 % CO2. The MSC properties of UC-MSCs at passage 5 such as osteoblast, chondroblast and adipocyte differentiation, and markers including CD13, CD14, CD29, CD34, CD44, CD45, CD73, CD90, CD105, and HLA-DR were confirmed. UC-MSCs also were analyzed for karyotype, expression of tumorigenesis related genes, cell cycle, doubling time as well as in vivo tumor formation in NOD/SCID mice. Control cells consisted of UC-MSCs cultured in DMEM/F12 plus 1 % antibiotic-antimycotic, and 10 % fetal bovine serum (FBS). All UC-MSC (n = 30) samples were successfully cultured in medium containing 7.5 and 10 % aPRP, 92 % of samples grew in 5.0 % aPRP, 86 % of samples in 2.5 % aPRP, and 72 % grew in 10 % FBS. UC-MSCs in these four groups exhibited similar marker profiles. Moreover, the proliferation rates in medium with PRP, especially 7.5 and 10 %, were significantly quicker compared with 2.5 and 5 % aPRP or 10 % FBS. These cells maintained a normal karyotype for 15 sub-cultures, and differentiated into osteoblasts, chondroblasts, and adipocytes. The analysis of pluripotent cell markers showed UC-MSCs maintained the expression of the oncogenes Nanog and Oct4 after long term culture but failed to transfer tumors in NOD/SCID mice. Replacing FBS with aPRP in the culture medium for UC tissues allowed the successful isolation of UC-MSCs that satisfy the minimum standards for clinical applications.

Entities:  

Keywords:  Activated platelet rich plasma; Clinical application of mesenchymal stem cells; Good manufacturing practice; UC–MSCs; Umbilical cord; Umbilical cord derived mesenchymal stem cells

Mesh:

Substances:

Year:  2015        PMID: 26679929     DOI: 10.1007/s10561-015-9541-6

Source DB:  PubMed          Journal:  Cell Tissue Bank        ISSN: 1389-9333            Impact factor:   1.522


  28 in total

1.  Accumulating Transcriptome Drift Precedes Cell Aging in Human Umbilical Cord-Derived Mesenchymal Stromal Cells Serially Cultured to Replicative Senescence.

Authors:  Danielle M Wiese; Cindy C Ruttan; Catherine A Wood; Barry N Ford; Lorena R Braid
Journal:  Stem Cells Transl Med       Date:  2019-03-28       Impact factor: 6.940

2.  Exosomal MicroRNAs Derived From Umbilical Mesenchymal Stem Cells Inhibit Hepatitis C Virus Infection.

Authors:  Xijing Qian; Chen Xu; Shuo Fang; Ping Zhao; Yue Wang; Houqi Liu; Wen Yuan; Zhongtian Qi
Journal:  Stem Cells Transl Med       Date:  2016-08-05       Impact factor: 6.940

3.  Platelet-rich plasma therapy and reproductive medicine.

Authors:  Adriana Bos-Mikich; Ricardo de Oliveira; Nilo Frantz
Journal:  J Assist Reprod Genet       Date:  2018-03-21       Impact factor: 3.412

4.  Production of endothelial progenitor cells from skin fibroblasts by direct reprogramming for clinical usages.

Authors:  Phuc Van Pham; Ngoc Bich Vu; Thuy Thi-Thanh Dao; Ha Thi-Ngan Le; Lan Thi Phi; Ngoc Kim Phan
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-10-24       Impact factor: 2.416

Review 5.  Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome.

Authors:  Maria Eugenia Fernández-Santos; Mariano Garcia-Arranz; Enrique J Andreu; Ana Maria García-Hernández; Miriam López-Parra; Eva Villarón; Pilar Sepúlveda; Francisco Fernández-Avilés; Damian García-Olmo; Felipe Prosper; Fermin Sánchez-Guijo; Jose M Moraleda; Agustin G Zapata
Journal:  Front Immunol       Date:  2022-06-09       Impact factor: 8.786

6.  Phenotypic and Functional Characterizations of Mesenchymal Stem/Stromal Cells Isolated From Human Cranial Bone Marrow.

Authors:  Kaichuang Yang; Ruijie Lu; Jianan Lu; Shucai Fan; Qiang Zhang; Zijian Lou; Yuyuan Ma; Gang Lu; Ruolang Pan; Jianmin Zhang
Journal:  Front Neurosci       Date:  2022-06-07       Impact factor: 5.152

Review 7.  Neonatal Encephalopathy: Update on Therapeutic Hypothermia and Other Novel Therapeutics.

Authors:  Ryan M McAdams; Sandra E Juul
Journal:  Clin Perinatol       Date:  2016-06-22       Impact factor: 3.430

Review 8.  An Update for Mesenchymal Stem Cell Therapy in Lupus Nephritis.

Authors:  Wenchao Li; Weiwei Chen; Lingyun Sun
Journal:  Kidney Dis (Basel)       Date:  2021-02-19

9.  Combined Use of Tocilizumab and Mesenchymal Stromal Cells in the Treatment of Severe Covid-19: Case Report.

Authors:  Alexandra Cristina Senegaglia; Carmen Lúcia Kuniyoshi Rebelatto; Claudio Luciano Franck; Juliana Souza Lima; Lidiane Maria Boldrini-Leite; Debora Regina Daga; Cleverson Alex Leitão; Patrícia Shigunov; Ana Paula de Azambuja; Elisa Bana; Daniela Boscaro Marsaro; Bruna Schaidt; Andressa Micosky; Valderez Ravaglio Jamur; Yara Schluga; Isadora May Vaz; Lisandro Lima Ribeiro; Alejandro Correa; E Paulo Roberto Slud Brofman
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

10.  Comparison of mesenchymal stromal cells from peritoneal dialysis effluent with those from umbilical cords: characteristics and therapeutic effects on chronic peritoneal dialysis in uremic rats.

Authors:  Yangchun Du; Ming Zong; Qiunong Guan; Zhongli Huang; Lan Zhou; Jing Cai; Gerald da Roza; Hao Wang; Hualin Qi; Yiping Lu; Caigan Du
Journal:  Stem Cell Res Ther       Date:  2021-07-13       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.